Suppliers and packagers for sucralfate

sucralfate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abon Pharms Llc	SUCRALFATE	sucralfate	SUSPENSION;ORAL	216726	ANDA	Torrent Pharmaceuticals Limited	13668-754-42	420 mL in 1 BOTTLE (13668-754-42)	2025-09-15
Abon Pharms Llc	SUCRALFATE	sucralfate	SUSPENSION;ORAL	216726	ANDA	Ingenus Pharmaceuticals, LLC	50742-386-42	420 mL in 1 BOTTLE (50742-386-42)	2024-11-21
Abon Pharms Llc	SUCRALFATE	sucralfate	SUSPENSION;ORAL	216726	ANDA	Richmond Pharmaceuticals, Inc.	54738-005-42	420 mL in 1 BOTTLE (54738-005-42)	2024-11-21
Amneal	SUCRALFATE	sucralfate	SUSPENSION;ORAL	209356	ANDA	AvKARE	42291-781-42	420 mL in 1 BOTTLE (42291-781-42)	2021-04-16

Sucralfate: Global Pharmaceutical Supply Chain Analysis

Last updated: February 19, 2026

Sucralfate, a cytoprotective agent used to treat peptic ulcers and gastroesophageal reflux disease, relies on a specialized supply chain. Key raw material sourcing, manufacturing processes, and geographic concentration of suppliers define its market dynamics. The global supply of sucralfate is characterized by a limited number of active pharmaceutical ingredient (API) manufacturers, primarily located in Asia, with China and India dominating production.

What are the primary raw materials for sucralfate production?

The synthesis of sucralfate involves several key chemical precursors. The primary raw material is sucrose, a widely available disaccharide. Sucralfate is chemically known as aluminum sucrose sulfate. The manufacturing process involves the sulfation of sucrose, followed by reaction with an aluminum compound.

• Sucrose: A common sugar, readily sourced globally from agricultural production. The quality and purity of sucrose are critical for API synthesis.
• Sulfur Trioxide (SO₃) or Chlorosulfonic Acid (ClSO₃H): These are potent sulfating agents used to convert sucrose into sucrose sulfate. Handling and sourcing these chemicals require strict safety protocols due to their corrosive nature.
• Aluminum Hydroxide (Al(OH)₃) or Aluminum Chloride (AlCl₃): These aluminum sources are used to form the final aluminum salt. The choice of aluminum compound can influence reaction conditions and final product characteristics.

The sourcing of these materials is generally not a bottleneck for sucralfate production due to their common industrial uses. However, fluctuations in the price or availability of high-purity grades of these chemicals can impact API manufacturing costs.

Who are the major global suppliers of sucralfate API?

The manufacturing of sucralfate active pharmaceutical ingredient (API) is concentrated among a select group of companies. Geographic concentration is a significant factor, with a majority of API production facilities located in Asia, particularly in China and India.

• China: Holds a substantial share of global sucralfate API manufacturing capacity. Companies in China benefit from established chemical industry infrastructure and cost advantages.
  • Jiangsu HEC Pharmaceutical Co., Ltd.
  • Zhejiang NHU Co., Ltd.
  • Nanjing Pharma Chemical Co., Ltd.
• India: Another significant producer of sucralfate API, known for its robust pharmaceutical manufacturing sector and compliance with international regulatory standards.
  • Divi's Laboratories Limited
  • Laurus Labs Limited
  • Aarti Drugs Limited

Other regions, including Europe and North America, have limited API manufacturing for sucralfate. This geographic concentration poses potential supply chain risks related to geopolitical stability, regulatory changes, and logistical disruptions. The number of active API manufacturers can fluctuate based on market demand and profitability.

What is the typical manufacturing process for sucralfate?

The production of sucralfate API involves a multi-step chemical synthesis. The process requires precise control of reaction conditions to ensure product purity and yield.

1. Sucrose Sulfation: Sucrose is reacted with a sulfating agent, typically sulfur trioxide complexed with a Lewis base or chlorosulfonic acid, under controlled temperatures. This reaction forms sucrose octasulfate.
2. Neutralization and Aluminum Salt Formation: The sucrose octasulfate is then neutralized and reacted with an aluminum source (e.g., aluminum hydroxide or aluminum chloride) in an aqueous medium. This step precipitates sucralfate as a complex polymer of aluminum sucrose sulfate.
3. Purification and Drying: The precipitated sucralfate is filtered, washed to remove residual impurities and salts, and then dried to obtain the final API powder.
4. Quality Control: Rigorous quality control testing is performed to ensure the API meets pharmacopoeial standards (e.g., USP, EP, JP) for identity, purity, assay, and absence of contaminants.

The manufacturing process is proprietary to some extent, with variations in sulfating agents, reaction conditions, and purification techniques employed by different manufacturers. These variations can impact the physical properties and dissolution characteristics of the final API.

What are the regulatory requirements for sucralfate API manufacturing?

Manufacturers of sucralfate API must adhere to stringent regulatory standards to ensure the safety, efficacy, and quality of the drug substance. These requirements are enforced by national and international health authorities.

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with GMP regulations established by bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). GMP covers all aspects of production, including personnel, premises, equipment, raw materials, processes, and documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products. This allows drug product manufacturers to reference the API information without having direct access to proprietary details.
• Pharmacopoeial Standards: Sucralfate API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). These monographs define tests for identity, purity, assay, and other quality attributes.
• Impurity Profiling: Manufacturers are required to identify and quantify impurities in the API. This includes related substances, residual solvents, and heavy metals. Limits for these impurities are set by regulatory guidelines.
• Site Inspections: Regulatory agencies conduct periodic inspections of API manufacturing sites to verify compliance with GMP and other applicable regulations.

Adherence to these requirements is essential for API suppliers to gain market access and for finished dosage form manufacturers to obtain marketing authorization for their sucralfate-containing products.

How is the global demand for sucralfate API influenced by finished product manufacturing?

The demand for sucralfate API is directly correlated with the production volumes of finished sucralfate dosage forms. These include oral suspensions, tablets, and granules.

• Prevalence of Gastrointestinal Disorders: The incidence and prevalence of peptic ulcers, GERD, and related gastrointestinal conditions are primary drivers of demand for sucralfate. Aging populations and lifestyle factors contribute to these conditions in many regions.
• Market Penetration of Generic Formulations: Sucralfate is an off-patent drug, leading to a competitive generic market. Generic manufacturers require a consistent and cost-effective supply of API to produce their finished products.
• Geographic Market Focus: Demand varies by region based on healthcare infrastructure, physician prescribing patterns, and local market access. Developed markets in North America and Europe, alongside growing markets in Asia and Latin America, contribute to global demand.
• Competition from Alternative Therapies: The market for acid-related gastrointestinal disorders is characterized by multiple treatment options, including proton pump inhibitors (PPIs) and H₂ receptor antagonists. The choice of therapy by healthcare providers influences the demand for sucralfate.
• Contract Manufacturing Organizations (CMOs): A significant portion of finished dosage form manufacturing is outsourced to CMOs. These CMOs procure API from various suppliers based on cost, quality, and regulatory compliance.

The relationship between API suppliers and finished product manufacturers is often characterized by long-term supply agreements, which provide stability for both parties. Fluctuations in finished product demand, driven by factors such as seasonal illness or changes in healthcare policy, directly translate to shifts in API demand.

What are the primary risks and challenges in the sucralfate supply chain?

The sucralfate supply chain, like many in the pharmaceutical industry, faces several risks and challenges that can impact availability and cost.

• Geographic Concentration of API Manufacturing: As noted, the heavy reliance on a few countries, particularly China and India, for API production creates vulnerability. Geopolitical tensions, trade disputes, or significant natural disasters in these regions could disrupt supply.
• Regulatory Changes: Evolving regulatory requirements in API manufacturing or for finished drug products can necessitate costly process changes or facility upgrades for suppliers. Stricter impurity limits or environmental regulations can pose challenges.
• Quality Control and Batch Variability: Ensuring consistent API quality across different suppliers and batches is crucial. Substandard API can lead to product recalls or regulatory action for finished dosage form manufacturers.
• Price Volatility of Raw Materials: While major raw materials are generally abundant, fluctuations in energy costs, agricultural yields (for sucrose), or the production of specialty chemicals can affect API manufacturing costs.
• Logistical Disruptions: Global shipping delays, port congestion, or transportation issues can impact the timely delivery of API to finished product manufacturers, especially for overseas shipments.
• Environmental Regulations: Chemical manufacturing is subject to increasingly stringent environmental regulations, particularly in regions with high concentrations of API production. Compliance costs can impact profitability and supply availability.
• Intellectual Property and Generic Competition: While sucralfate is off-patent, ensuring the integrity of the supply chain against counterfeit or substandard products remains a concern.

Mitigation strategies include diversifying supplier bases, maintaining robust quality assurance systems, and developing contingency plans for logistical disruptions.

Key Takeaways

The sucralfate pharmaceutical supply chain is characterized by a concentrated API manufacturing base, primarily in China and India. Sourcing of raw materials like sucrose, sulfur trioxide, and aluminum compounds is generally stable. Demand for sucralfate API is driven by the prevalence of gastrointestinal disorders and the competitive landscape of generic finished dosage forms. Key risks include geographic concentration of API production, regulatory shifts, and potential logistical disruptions.

FAQs

1. What is the primary function of sucralfate in pharmaceutical formulations?

Sucralfate functions as a cytoprotective agent by forming a protective barrier over ulcerated or inflamed tissue in the gastrointestinal tract. This barrier protects the affected area from further damage by gastric acid, pepsin, and bile salts, thereby promoting healing.

2. Are there any patented manufacturing processes for sucralfate API that could limit supply?

Sucralfate itself is an old drug, and its fundamental manufacturing process is off-patent. While specific process optimizations or polymorphs might be subject to individual patents, the core synthesis is widely accessible, contributing to its generic availability.

3. How do regulatory agencies ensure the quality of sucralfate API sourced from different countries?

Regulatory agencies like the FDA and EMA conduct GMP inspections of manufacturing facilities worldwide. They also review Drug Master Files (DMFs) submitted by API manufacturers and require finished product manufacturers to demonstrate that their API suppliers meet established quality standards and pharmacopoeial specifications.

4. What are the typical packaging and storage requirements for sucralfate API?

Sucralfate API is typically supplied as a white or off-white, odorless, and tasteless powder. It should be stored in well-closed containers, protected from light and moisture, at controlled room temperature to maintain its stability and prevent degradation. Specific storage conditions may be detailed in the manufacturer's Certificate of Analysis.

5. Can the use of alternative therapies impact the long-term demand for sucralfate API?

Yes, the demand for sucralfate API is influenced by the availability and efficacy of alternative therapies for acid-related gastrointestinal disorders, such as proton pump inhibitors (PPIs) and H₂ receptor antagonists. Prescribing patterns and clinical guidelines for these conditions can shift demand away from or towards sucralfate.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidances-drug-development-and-submission/drug-master-files [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/compliance-regulatory-affairs/good-manufacturing-practice [3] United States Pharmacopeia. (n.d.). Sucralfate Monograph. Retrieved from USP-NF (specific edition required for access) [4] World Health Organization. (n.d.). Good manufacturing practices for pharmaceutical products. Retrieved from https://www.who.int/teams/health-products-policy-and-standards/standards-and-specifications/good-manufacturing-practices